
Zelma and William Reid Commit $10 million to Establish Program for Pancreatic Cancer Interception and Prevention
Key Takeaways
- A $10 million gift establishes an interception-focused program targeting earlier detection and preemptive intervention for individuals at elevated pancreatic cancer risk.
- Co-leadership integrates surgical cyst management, endoscopic early-detection expertise, and hereditary-risk clinical genetics to align screening, diagnosis, interception, and treatment.
A gift to MD Anderson Cancer Center supports innovative pancreatic cancer research.
The collaborative program brings together a multidisciplinary team of experts at UT MD Anderson, co-led by
“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said
Pancreatic cancer remains one of the deadliest forms of cancer, often because it is diagnosed after the disease has already advanced. Through the new program, Kim and colleagues will work to change that reality through novel approaches that identify individuals at increased risk, allowing physicians to intervene before cancer develops or spreads.
“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim said. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”
The Pancreatic Cancer High-Risk Interception Program will serve individuals at elevated risk for pancreatic cancer, providing expert evaluation, advanced imaging, molecular diagnostics and coordinated care. By combining artificial intelligence (AI)-driven risk assessment, next-generation DNA testing and personalized surveillance, the aim is to identify pancreatic cancer at its earliest and most treatable stages.
Leveraging world-class imaging technologies, sophisticated laboratory testing and decades of multidisciplinary expertise in pancreatic cancer, the program is designed to provide highly precise risk assessment, monitoring strategies and timely intervention when needed. For example, physicians will be able to accurately assess whether a pancreatic cyst is likely to develop into cancer, allowing them to intervene if necessary or spare patients from unnecessary treatments. Equally important, the program will expand access to specialized screening and prevention services, connecting more high-risk individuals and families to expert care before cancer develops or progresses.
A comprehensive biospecimen and data platform will support groundbreaking research into early detection and disease interception, while a robust training program will help develop future leaders in pancreatic cancer prevention. Together, these integrated capabilities represent a transformative shift toward detecting pancreatic cancer sooner, intercepting disease before it becomes life-threatening and advancing a future where more patients can benefit from precision prevention and early intervention.
For the Reids, the gift represents an investment in a future where fewer families experience the devastating impact of pancreatic cancer.
“For nearly 30 years, we have admired UT MD Anderson's commitment to advancing research and improving patient care,” Zelma Reid said. “We are inspired by the work being led by Drs. Kim, Bhutani and McAllister, and we are honored to support a program that has the potential to intercept pancreatic cancer earlier and save more lives. We hope this investment helps create new possibilities for patients and families for generations to come.”
Related to this article








